OTLK Logo

Outlook Therapeutics, Inc. (OTLK) 

NASDAQ
Market Cap
$122.3M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
49 of 774
Rank in Industry
36 of 432

Largest Insider Buys in Sector

OTLK Stock Price History Chart

OTLK Stock Performance

About Outlook Therapeutics, Inc.

Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with IPCA Laboratories Limited; Laboratorios Liomont, S.A. de C.V.; BioLexis Pte. …

Insider Activity of Outlook Therapeutics, Inc.

Over the last 12 months, insiders at Outlook Therapeutics, Inc. have bought $5.08M and sold $0 worth of Outlook Therapeutics, Inc. stock.

On average, over the past 5 years, insiders at Outlook Therapeutics, Inc. have bought $9.86M and sold $724,536 worth of stock each year.

Highest buying activity among insiders over the last 12 months: Syntone Ventures LLC (10 percent owner) — $5M. KENYON LAWRENCE A (Chief Financial Officer) — $28,446. Evanson Jeff (CHIEF COMMERCIAL OFFICER) — $26,243.

The last purchase of 5,000 shares for transaction amount of $28,446 was made by KENYON LAWRENCE A (Chief Financial Officer) on 2024‑09‑26.

List of Insider Buy and Sell Transactions, Outlook Therapeutics, Inc.

2024-09-26PurchaseChief Financial Officer
5,000
0.0216%
$5.69$28,4460.00%
2024-04-15Purchase10 percent owner
714,286
2.6874%
$7.00$5M-15.02%
2024-03-28Purchasedirector
1,881.71
0.0143%
$11.82$22,242-37.92%
2024-03-07PurchaseCHIEF COMMERCIAL OFFICER
62,484
0.0245%
$0.42$26,243-9.78%
2023-04-20SaleChief Operations Officer
520,000
0.2181%
$1.14$590,200-62.27%
2023-01-20SaleChief Commercial Officer
267,000
0.1196%
$1.11$296,370-0.92%
2023-01-19SaleChief Commercial Officer
103,255
0.0462%
$1.22$125,971-10.00%
2023-01-18SaleChief Commercial Officer
33,738
0.015%
$1.25$42,173-12.90%
2023-01-17SaleChief Commercial Officer
27,162
0.0122%
$1.31$35,582-15.63%
2022-10-07Purchasedirector
30,000
0.0135%
$1.29$38,700-9.92%
2022-10-07Purchasedirector
3,600
0.0016%
$1.27$4,572-9.92%
2022-10-06Purchasedirector
29,743
0.0134%
$1.29$38,368-9.52%
2022-10-05Purchasedirector
15,662
0.0068%
$1.23$19,264-8.80%
2022-10-04Purchasedirector
95,541
0.0427%
$1.29$123,248-10.24%
2022-09-29Purchase
88,797
0.0438%
$1.24$110,500-3.36%
2022-06-21PurchaseChief Operating Officer
10,000
0.0045%
$1.05$10,500+8.57%
2022-06-21PurchaseCEO and President
19,925
0.0091%
$1.06$21,121+8.57%
2022-03-01Purchasedirector
27,708
0.0127%
$1.69$46,827-30.95%
2022-02-28Purchasedirector
6,000
0.0027%
$1.60$9,600-28.83%
2022-02-24Purchasedirector
41,160
0.0167%
$1.46$60,094-28.66%

Insider Historical Profitability

50.18%
Syntone Ventures LLC10 percent owner
1705438
7.2094%
$5.1730+28.25%
Evanson JeffCHIEF COMMERCIAL OFFICER
808459
3.4176%
$5.1726
KENYON LAWRENCE AChief Financial Officer
5946
0.0251%
$5.1733+17.42%
Haddadin Yezan Muntherdirector
5049
0.0213%
$5.1760+52.96%
Sukhtian Ghiath M.
27834257
117.6646%
$5.1720+92.17%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Tang Capital Management, LLC$19.34M6.921.62MNew+$19.34M0.07
Great Point Partners$17.67M6.321.48MNew+$17.67M2.96
Armistice Capital Llc$8.53M3.05714,285New+$8.53M0.03
Sphera Fund$6.82M2.44571,429New+$6.82M0.04
BlackRock$6.02M2.15503,988-95.14%-$117.76M<0.0001
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.